Upstream

Upstream Medical Technologies has developed a final test based on biomarkers for the rapid and accurate diagnosis of heart disease and related clinical complications. Upstream Medical Technologies will commercialize a set of novel biomarkers for cardiac disease diagnosis. These biomarkers were developed at the Christchurch Heart Institute (CHI), a Center of Research Excellence at the University of Otago, Christchurch, New Zealand. Researchers at CHI were the first in the world to discover protein fragments in the blood known as signal peptides (Siriwardena, M (2010) Circulation 122; 255). This discovery led to a new class of biomarkers that can be used to diagnose various cardiovascular diseases and clinically relevant conditions.